Baidu
map

J Affect Disord:动脉自旋标记检测重度抑郁患者经6周艾司西酞普兰治疗后局部脑血流量的改变

2016-05-09 MedSci MedSci原创

研究背景:少部分研究曾使用动脉自旋标记评估重度抑郁患者局部脑血流量。然而,艾司西酞普兰治疗期间局部脑血流量改变未被研究过。我们使用动脉自旋标记调查6周艾司西酞普兰治疗对重度抑郁患者局部脑血流量的影响。研究方法:我们入组53例重度抑郁的患者和36例对照组进行动脉自旋标记检查(T1,基线)。病人然后接受6周艾司西酞普兰治疗,其中27位再次接受扫描(T2)。我们使用选择好的感兴趣区来发现对照组和病人之间

研究背景:少部分研究曾使用动脉自旋标记评估重度抑郁患者局部脑血流量。然而,艾司西酞普兰治疗期间局部脑血流量改变未被研究过。我们使用动脉自旋标记调查6周艾司西酞普兰治疗对重度抑郁患者局部脑血流量的影响。

研究方法:我们入组53例重度抑郁的患者和36例对照组进行动脉自旋标记检查(T1,基线)。病人然后接受6周艾司西酞普兰治疗,其中27位再次接受扫描(T2)。我们使用选择好的感兴趣区来发现对照组和病人之间在T1的区别,并比较病人T2局部脑血流量和对照组T1脑血流量的差异。我们也对比了病人T1和T2局部脑血流量来评估他们对艾司西酞普兰的反应。

研究结果:6周艾司西酞普兰的治疗后,病人左前颞叶、额中回、额后回的局部脑血流量,显示具有比对照组更高的T1的情况减少。病人右侧舌回的局部脑血流量在T2上仍显著较低。

研究局限:我们没有安慰剂对照组,并且行T2的病人少

研究结论:在重症抑郁患者中,6州的艾司西酞普兰治疗可以带来显著的大部分区域局部脑血流量趋向正常的改变。右侧舌回局部脑血流量异常的持续可能是重症抑郁的一个标志。

原始出处:

Kaichi Y1, Okada G2, Takamura M2, Toki S,et al,Changes in the regional cerebral blood flow detected by arterial spin labeling after 6-week escitalopram treatment for major depressive disorder.J Affect Disord. 2016 Apr;194:135-43. doi: 10.1016.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2042257, encodeId=cc5b204225e06, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Apr 05 00:09:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012091, encodeId=a973201209103, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jan 09 02:09:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779417, encodeId=0fb81e794176a, content=<a href='/topic/show?id=48dc20680a' target=_blank style='color:#2F92EE;'>#Affect#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2068, encryptionId=48dc20680a, topicName=Affect)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat Jun 25 21:09:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784388, encodeId=97db1e84388d5, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Feb 28 15:09:00 CST 2017, time=2017-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075895, encodeId=1b2a20e589582, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jun 17 07:09:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632509, encodeId=1c4a163250990, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Wed May 25 06:09:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771566, encodeId=bbb81e71566f3, content=<a href='/topic/show?id=0a91333227e' target=_blank style='color:#2F92EE;'>#动脉自旋标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33322, encryptionId=0a91333227e, topicName=动脉自旋标记)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc0d38318388, createdName=xjy15, createdTime=Fri Mar 03 00:09:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405691, encodeId=d5ec140569177, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568384, encodeId=474115683847f, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85297, encodeId=9b938529eeb, content=学习了,希望有新的突破!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Tue May 10 12:37:00 CST 2016, time=2016-05-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2042257, encodeId=cc5b204225e06, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Apr 05 00:09:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012091, encodeId=a973201209103, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jan 09 02:09:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779417, encodeId=0fb81e794176a, content=<a href='/topic/show?id=48dc20680a' target=_blank style='color:#2F92EE;'>#Affect#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2068, encryptionId=48dc20680a, topicName=Affect)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat Jun 25 21:09:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784388, encodeId=97db1e84388d5, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Feb 28 15:09:00 CST 2017, time=2017-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075895, encodeId=1b2a20e589582, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jun 17 07:09:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632509, encodeId=1c4a163250990, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Wed May 25 06:09:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771566, encodeId=bbb81e71566f3, content=<a href='/topic/show?id=0a91333227e' target=_blank style='color:#2F92EE;'>#动脉自旋标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33322, encryptionId=0a91333227e, topicName=动脉自旋标记)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc0d38318388, createdName=xjy15, createdTime=Fri Mar 03 00:09:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405691, encodeId=d5ec140569177, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568384, encodeId=474115683847f, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85297, encodeId=9b938529eeb, content=学习了,希望有新的突破!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Tue May 10 12:37:00 CST 2016, time=2016-05-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2042257, encodeId=cc5b204225e06, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Apr 05 00:09:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012091, encodeId=a973201209103, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jan 09 02:09:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779417, encodeId=0fb81e794176a, content=<a href='/topic/show?id=48dc20680a' target=_blank style='color:#2F92EE;'>#Affect#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2068, encryptionId=48dc20680a, topicName=Affect)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat Jun 25 21:09:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784388, encodeId=97db1e84388d5, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Feb 28 15:09:00 CST 2017, time=2017-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075895, encodeId=1b2a20e589582, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jun 17 07:09:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632509, encodeId=1c4a163250990, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Wed May 25 06:09:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771566, encodeId=bbb81e71566f3, content=<a href='/topic/show?id=0a91333227e' target=_blank style='color:#2F92EE;'>#动脉自旋标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33322, encryptionId=0a91333227e, topicName=动脉自旋标记)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc0d38318388, createdName=xjy15, createdTime=Fri Mar 03 00:09:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405691, encodeId=d5ec140569177, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568384, encodeId=474115683847f, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85297, encodeId=9b938529eeb, content=学习了,希望有新的突破!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Tue May 10 12:37:00 CST 2016, time=2016-05-10, status=1, ipAttribution=)]
    2016-06-25 chenwq08
  4. [GetPortalCommentsPageByObjectIdResponse(id=2042257, encodeId=cc5b204225e06, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Apr 05 00:09:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012091, encodeId=a973201209103, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jan 09 02:09:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779417, encodeId=0fb81e794176a, content=<a href='/topic/show?id=48dc20680a' target=_blank style='color:#2F92EE;'>#Affect#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2068, encryptionId=48dc20680a, topicName=Affect)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat Jun 25 21:09:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784388, encodeId=97db1e84388d5, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Feb 28 15:09:00 CST 2017, time=2017-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075895, encodeId=1b2a20e589582, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jun 17 07:09:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632509, encodeId=1c4a163250990, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Wed May 25 06:09:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771566, encodeId=bbb81e71566f3, content=<a href='/topic/show?id=0a91333227e' target=_blank style='color:#2F92EE;'>#动脉自旋标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33322, encryptionId=0a91333227e, topicName=动脉自旋标记)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc0d38318388, createdName=xjy15, createdTime=Fri Mar 03 00:09:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405691, encodeId=d5ec140569177, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568384, encodeId=474115683847f, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85297, encodeId=9b938529eeb, content=学习了,希望有新的突破!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Tue May 10 12:37:00 CST 2016, time=2016-05-10, status=1, ipAttribution=)]
    2017-02-28 cmsvly
  5. [GetPortalCommentsPageByObjectIdResponse(id=2042257, encodeId=cc5b204225e06, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Apr 05 00:09:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012091, encodeId=a973201209103, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jan 09 02:09:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779417, encodeId=0fb81e794176a, content=<a href='/topic/show?id=48dc20680a' target=_blank style='color:#2F92EE;'>#Affect#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2068, encryptionId=48dc20680a, topicName=Affect)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat Jun 25 21:09:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784388, encodeId=97db1e84388d5, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Feb 28 15:09:00 CST 2017, time=2017-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075895, encodeId=1b2a20e589582, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jun 17 07:09:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632509, encodeId=1c4a163250990, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Wed May 25 06:09:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771566, encodeId=bbb81e71566f3, content=<a href='/topic/show?id=0a91333227e' target=_blank style='color:#2F92EE;'>#动脉自旋标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33322, encryptionId=0a91333227e, topicName=动脉自旋标记)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc0d38318388, createdName=xjy15, createdTime=Fri Mar 03 00:09:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405691, encodeId=d5ec140569177, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568384, encodeId=474115683847f, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85297, encodeId=9b938529eeb, content=学习了,希望有新的突破!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Tue May 10 12:37:00 CST 2016, time=2016-05-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2042257, encodeId=cc5b204225e06, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Apr 05 00:09:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012091, encodeId=a973201209103, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jan 09 02:09:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779417, encodeId=0fb81e794176a, content=<a href='/topic/show?id=48dc20680a' target=_blank style='color:#2F92EE;'>#Affect#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2068, encryptionId=48dc20680a, topicName=Affect)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat Jun 25 21:09:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784388, encodeId=97db1e84388d5, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Feb 28 15:09:00 CST 2017, time=2017-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075895, encodeId=1b2a20e589582, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jun 17 07:09:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632509, encodeId=1c4a163250990, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Wed May 25 06:09:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771566, encodeId=bbb81e71566f3, content=<a href='/topic/show?id=0a91333227e' target=_blank style='color:#2F92EE;'>#动脉自旋标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33322, encryptionId=0a91333227e, topicName=动脉自旋标记)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc0d38318388, createdName=xjy15, createdTime=Fri Mar 03 00:09:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405691, encodeId=d5ec140569177, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568384, encodeId=474115683847f, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85297, encodeId=9b938529eeb, content=学习了,希望有新的突破!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Tue May 10 12:37:00 CST 2016, time=2016-05-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2042257, encodeId=cc5b204225e06, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Apr 05 00:09:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012091, encodeId=a973201209103, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jan 09 02:09:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779417, encodeId=0fb81e794176a, content=<a href='/topic/show?id=48dc20680a' target=_blank style='color:#2F92EE;'>#Affect#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2068, encryptionId=48dc20680a, topicName=Affect)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat Jun 25 21:09:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784388, encodeId=97db1e84388d5, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Feb 28 15:09:00 CST 2017, time=2017-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075895, encodeId=1b2a20e589582, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jun 17 07:09:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632509, encodeId=1c4a163250990, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Wed May 25 06:09:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771566, encodeId=bbb81e71566f3, content=<a href='/topic/show?id=0a91333227e' target=_blank style='color:#2F92EE;'>#动脉自旋标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33322, encryptionId=0a91333227e, topicName=动脉自旋标记)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc0d38318388, createdName=xjy15, createdTime=Fri Mar 03 00:09:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405691, encodeId=d5ec140569177, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568384, encodeId=474115683847f, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85297, encodeId=9b938529eeb, content=学习了,希望有新的突破!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Tue May 10 12:37:00 CST 2016, time=2016-05-10, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2042257, encodeId=cc5b204225e06, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Apr 05 00:09:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012091, encodeId=a973201209103, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jan 09 02:09:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779417, encodeId=0fb81e794176a, content=<a href='/topic/show?id=48dc20680a' target=_blank style='color:#2F92EE;'>#Affect#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2068, encryptionId=48dc20680a, topicName=Affect)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat Jun 25 21:09:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784388, encodeId=97db1e84388d5, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Feb 28 15:09:00 CST 2017, time=2017-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075895, encodeId=1b2a20e589582, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jun 17 07:09:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632509, encodeId=1c4a163250990, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Wed May 25 06:09:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771566, encodeId=bbb81e71566f3, content=<a href='/topic/show?id=0a91333227e' target=_blank style='color:#2F92EE;'>#动脉自旋标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33322, encryptionId=0a91333227e, topicName=动脉自旋标记)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc0d38318388, createdName=xjy15, createdTime=Fri Mar 03 00:09:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405691, encodeId=d5ec140569177, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568384, encodeId=474115683847f, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85297, encodeId=9b938529eeb, content=学习了,希望有新的突破!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Tue May 10 12:37:00 CST 2016, time=2016-05-10, status=1, ipAttribution=)]
    2016-05-11 chg122
  9. [GetPortalCommentsPageByObjectIdResponse(id=2042257, encodeId=cc5b204225e06, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Apr 05 00:09:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012091, encodeId=a973201209103, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jan 09 02:09:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779417, encodeId=0fb81e794176a, content=<a href='/topic/show?id=48dc20680a' target=_blank style='color:#2F92EE;'>#Affect#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2068, encryptionId=48dc20680a, topicName=Affect)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat Jun 25 21:09:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784388, encodeId=97db1e84388d5, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Feb 28 15:09:00 CST 2017, time=2017-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075895, encodeId=1b2a20e589582, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jun 17 07:09:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632509, encodeId=1c4a163250990, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Wed May 25 06:09:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771566, encodeId=bbb81e71566f3, content=<a href='/topic/show?id=0a91333227e' target=_blank style='color:#2F92EE;'>#动脉自旋标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33322, encryptionId=0a91333227e, topicName=动脉自旋标记)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc0d38318388, createdName=xjy15, createdTime=Fri Mar 03 00:09:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405691, encodeId=d5ec140569177, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568384, encodeId=474115683847f, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85297, encodeId=9b938529eeb, content=学习了,希望有新的突破!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Tue May 10 12:37:00 CST 2016, time=2016-05-10, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=2042257, encodeId=cc5b204225e06, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Apr 05 00:09:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012091, encodeId=a973201209103, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jan 09 02:09:00 CST 2017, time=2017-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779417, encodeId=0fb81e794176a, content=<a href='/topic/show?id=48dc20680a' target=_blank style='color:#2F92EE;'>#Affect#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2068, encryptionId=48dc20680a, topicName=Affect)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=365d170, createdName=chenwq08, createdTime=Sat Jun 25 21:09:00 CST 2016, time=2016-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784388, encodeId=97db1e84388d5, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Tue Feb 28 15:09:00 CST 2017, time=2017-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075895, encodeId=1b2a20e589582, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Jun 17 07:09:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632509, encodeId=1c4a163250990, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Wed May 25 06:09:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771566, encodeId=bbb81e71566f3, content=<a href='/topic/show?id=0a91333227e' target=_blank style='color:#2F92EE;'>#动脉自旋标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33322, encryptionId=0a91333227e, topicName=动脉自旋标记)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc0d38318388, createdName=xjy15, createdTime=Fri Mar 03 00:09:00 CST 2017, time=2017-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405691, encodeId=d5ec140569177, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568384, encodeId=474115683847f, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Wed May 11 14:09:00 CST 2016, time=2016-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=85297, encodeId=9b938529eeb, content=学习了,希望有新的突破!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=ebe61630855, createdName=1dd8a7c5m95(暂无匿称), createdTime=Tue May 10 12:37:00 CST 2016, time=2016-05-10, status=1, ipAttribution=)]
    2016-05-10 1dd8a7c5m95(暂无匿称)

    学习了,希望有新的突破!

    0

Baidu
map
Baidu
map
Baidu
map